Stockreport

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

Redhill Biopharma Ltd. - American Depositary Shares  (RDHL) 
US:NASDAQ Investor Relations: ir.redhillbio.com/investor-relations
PDF RHB-1021 is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology su [Read more]